Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9650334 | 0.83 | GAA (0.37) | CYP1A2CYP3A4CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL16311781 | 0.81 | IDO1 (0.40) | LMNAAGTR1CYP1A2ACHECYP2D6 | |
| SCHEMBL9715173 | 0.79 | KRAS (0.30) | — | |
| SCHEMBL3234431 | 0.79 | ACHE (0.44) | LMNAAGTR1CYP1A2ACHECYP3A4 | |
| SCHEMBL9647516 | 0.79 | CYP3A4 (0.39) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9650911 | 0.78 | CES2 (0.36) | CYP3A4CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14143601 | 0.78 | LMNA (0.40) | LMNAAGTR1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL13086065 | 0.76 | LMNA (0.42) | LMNAAGTR1CYP1A2HTTPOLB | |
| SCHEMBL10075131 | 0.76 | LMNA (0.42) | LMNAAGTR1CYP1A2HTTPOLB | |
| SCHEMBL10075125 | 0.76 | LMNA (0.42) | LMNAAGTR1CYP1A2HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| US-20140288110-A1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20140288110-A1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | EVOLVA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | EVOLVA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8536196-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2013-09-17 | — | — | US | disclosed |
| US-8536196-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2013-09-17 | — | — | US | disclosed |
| US-20110178112-A1 | PPAR Modulators | EVOLVA SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20110178112-A1 | PPAR Modulators | EVOLVA SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| US-5166377-A | Thromboxane A2 antagonist as coagulants or vasoconstrictors | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-11-24 | — | — | US | disclosed |
| US-4745198-A | CARDIOVASCULAR DISORDERS, BRONCHODILATOR AGENTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-17 | — | — | US | disclosed |
| US-4567197-A | THORMBOXANE A2 ANTAGONISTS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178112-A1 | PPAR Modulators | PPARD, PPARG, PPARA | LMNA 3708/4885AGTR1 1596/4885CYP1A2 1093/4885 |
| US-20140288110-A1 | PPAR MODULATORS | PPARD, PPARG, PPARA | LMNA 3708/4885AGTR1 1596/4885CYP1A2 1093/4885 |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | LMNA 2910/4885AGTR1 846/4885CYP1A2 592/4885 |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | PPARD, PPARG, PPARA | LMNA 2910/4885AGTR1 846/4885CYP1A2 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.